ER membrane protein complex subunit 4Genealiases: PIG17 · TMEM85
Q-omics provides the consensus-scored EMC4 profile across patient tissues and cancer cell-line models. EMC4 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, EMC4 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, EMC4 RNA expression shows 18,899 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, and ACC as cancer lineages where EMC4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EMC4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EMC4 survival associations across molecular data types. EMC4 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EMC4 RNA expression–survival associations across cancer types. High EMC4 expression shows unfavorable associations in HNSC, UVM, KICH, STAD, ACC and BLCA. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for EMC4 RNA expression.
This table summarizes EMC4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for EMC4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EMC4 shows higher tumor expression in HNSC, KIRC, LIHC, COAD, CHOL and BLCA. The HNSC box plot shows higher EMC4 RNA expression in tumor versus normal tissue (log2 FC = +0.556, t-test p < 0.001).
This table shows molecular features associated with EMC4 in patient tissues and cancer cell lines. In patient samples, EMC4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, EMC4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and STOMACH.
